Important Notice

For any urgent eye health issue please call our office at 503-371-4350. This line is monitored continuously and our on-call doctor will be contacted during non-clinic hours.

Coronavirus Advisory

Updated 7/31/20

A Message to our Patients:

In spite of the ongoing coronavirus pandemic, we believe that sight is among our most valued faculties and should remain a priority. Our office is open, and we are continuing to make every effort to provide the best eye care that we possibly can while ensuring the safety of you and our staff. We have implemented precautions to reduce the risk of disease exposure, and in the following post we will outline our current policies.

Please stay healthy and safe and let us know if there is anything we can do to help.


Andrew Westfall, MD
Justin Baynham, MD
Monica Michelotti, MD
Scott McClintic, MD


The majority of our patient visits are important to the preservation of vision, and we are encouraging our patients to keep their scheduled appointments. If you previously cancelled an appointment due to the COVID threat, please contact our office to discuss a plan for rescheduling.

Also, if one or more of the following applies to you, please call our office prior to your appointment:

  • You have had a fever, sore throat, cough, or other respiratory symptoms within the last 14 days.
  • You have been directly exposed to someone with known or suspected COVID-19.
  • You are at high risk for complications relating to the possible development of COVID-19 (e.g., patients of advanced age or those with underlying medical conditions).

With regard to eye injection appointments, please read this statement from our providers:

“Eye injections are intended to reduce the risk of vision loss by temporarily suppressing disease activity. Delays in treatment beyond what has been recommended by your physician could potentially lead to permanent loss of vision.  If a delay does occur, treatment can often be restarted and in some cases the vision may be at least partially restored; however, the exact degree of risk for each treatment delay is impossible to know up front.  Each patient must make a personal decision regarding their risk of potential harm from infection exposure versus their risk of losing vision.  If you do choose to keep your appointment, we will take all reasonable and known precautions to keep you safe during your visit.”


The following protocols have been put in place to protect both patients and our staff:

  • When possible, please call to check in from your car and wait there until you are called inside for your appointment. This will minimize the number of patients at our front desk and in our waiting rooms.
  • Family members with any signs of fever or respiratory illness should avoid entering our building.
  • Patients are encouraged to maintain at least 6 feet of distancing unless they are involved in a necessary interaction with staff or providers. Please apply this to your choice of seating in our waiting rooms.
  • There will be no hand shaking between patients, staff, and providers.
  • Exam rooms and instruments will be disinfected after each patient encounter.
  • Waiting rooms will be disinfected at lunch and at the end of the day.
  • Physicians and staff members will be wearing masks.
  • Mask wearing by patients and visitors is encouraged.

New Patient Forms

If you are a new patient, you can save time in our office by completing your registration forms at home. Please print and complete all forms and bring them with you to your appointment.

Medical Records Release

If you would like us to release your medical records to yourself or another entity, please fill out the following form and return it to our office.

Our Team

Clinical Trials at Retina Consultants

Wet (Neovascular) Age-Related Macular Degeneration


Description: Clinical trial evaluating whether the use of a higher dose of aflibercept, which is already FDA-approved for treatment of wet age-related macular degeneration (AMD), will allow for less frequent eye injections in wet AMD.

Full Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration

Sponsor: Bayer Pharmaceuticals

Principal Investigator: Scott McClintic, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Dry (Atrophic) Age-Related Macular Degeneration


Description: Patients with advanced dry AMD provide a saliva sample to screen for AMD-associated genes. If targeted AMD-associated genes are present, subjects may be invited to participate in other trials, including a more extensive natural history study called SCOPE.

Sponsor: Gyroscope Therapeutics

Principal Investigator: Monica Michelotti, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Diabetic Retinopathy

DRCR (Diabetic Retinopathy Clinical Research network)

Principal Investigator: Scott McClintic, MD

Study Coordinator: Marina Sprauer, LPN

Status: Not currently enrolling

JAEB Center for Health Research

Completed Clinical Trials at Retina Consultants


A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion.


A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration.

VIEW1 Extension Study

An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration.

Disorders We Treat

  • Central Serous Retinopathy
  • Diabetic Retinopathy
  • Macular Degeneration
  • Retinal Detachment
  • Retinal Tear
  • Cystoid Macular Edema
  • Endophthalmitis or Intraocular Infection (Infection Inside Eye)
  • Flashes and Floaters
  • Macular Pucker (Epiretinal Membrane)
  • Macular Hole
  • Neovascular Glaucoma
  • Pars Planitis
  • Pattern Dystrophy
  • PVR (Proliferative Vitreo-retinopathy)
  • Retinal Artery Occlusion
  • Retinal Vein Occlusion
  • Removal of Cataract Fragments or Dislocated Lens Implants
  • Uveitis
  • Vitreous Detachment
  • Vitreous Hemorrhage

Testing and Treatment

We Provide Diagnostic Testing

  • Fluorescein Angiography (FA)
  • Fundus Autofluorescence (FAF)
  • Indocyanine Green Angiography (ICGA)
  • Optical Coherence Tomography (OCT)
  • Ultrasonography (B-scan)

We Offer Comprehensive Treatment

  • Injection of Intravitreal Drugs
  • Insertion of Intravitreal Implants
  • Retinal Laser Treatments (Photocoagulation)
  • Removal of Intraocular Fluid for Culture or Biopsy
  • Pneumatic Retinopexy
  • Vitreoretinal Surgical Procedures (including Vitrectomy and Scleral Buckling)
  • Vitamins and Nutrition Education

If you have questions or concerns